Telix Pharmaceuticals Valuation
| TLX Stock | 6.54 0.11 1.71% |
At this time, the company appears to be undervalued. Telix Pharmaceuticals has a current Real Value of USD9.97 per share. The regular price of the company is USD6.54. Our model measures the value of Telix Pharmaceuticals from inspecting the company fundamentals such as insignificant Operating Margin, shares outstanding of 334.72 M, and Return On Equity of 0.0314 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Telix Pharmaceuticals' valuation include:
Price Book 5.1009 | Enterprise Value | Enterprise Value Ebitda 57.0563 | Price Sales 3.2403 | Forward PE 54.9451 |
Undervalued
Today
Please note that Telix Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Telix Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telix Stock. However, Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.54 | Real 9.97 | Target 20.9 | Hype 6.37 |
The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telix Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telix Pharmaceuticals Limited helps investors to forecast how Telix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Telix Pharmaceuticals' intrinsic value based on its ongoing forecasts of Telix Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Telix Pharmaceuticals' closest peers.
Telix Pharmaceuticals Cash |
|
Telix Revenue by Product
Telix Pharmaceuticals Total Value Analysis
Telix Pharmaceuticals Limited is at this time expected to have company total value of 2.38 B with market capitalization of 3.28 B, debt of 581.45 M, and cash on hands of . Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Telix Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.38 B | 3.28 B | 581.45 M |
Telix Pharmaceuticals Investor Information
The company had not issued any dividends in recent years. Telix Pharmaceuticals had 1:1000 split on the 29th of October 2013. Based on the key indicators related to Telix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Telix Pharmaceuticals Limited is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.Telix Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Telix Pharmaceuticals has an asset utilization ratio of 51.65 percent. This suggests that the Company is making USD0.52 for each dollar of assets. An increasing asset utilization means that Telix Pharmaceuticals Limited is more efficient with each dollar of assets it utilizes for everyday operations.Telix Pharmaceuticals Profitability Analysis
Based on Telix Pharmaceuticals' profitability indicators, Telix Pharmaceuticals Limited is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess Telix Pharmaceuticals' ability to earn profits and add value for shareholders.Net Income | First Reported 2000-09-30 | Previous Quarter 38.2 M | Current Value -3.5 M | Quarterly Volatility 17.2 M |
For Telix Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telix Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telix Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telix Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telix Pharmaceuticals over time as well as its relative position and ranking within its peers.
Telix Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Telix Pharmaceuticals is estimated to be 0.089875 with future projections ranging from a low of 0.06475 to a high of 0.115. Telix Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at 0.02. Please be aware that the consensus of earnings estimates for Telix Pharmaceuticals Limited is based on EPS before non-recurring items and includes expenses related to employee stock options.Telix Pharmaceuticals Earnings Estimation Breakdown
The calculation of Telix Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Telix Pharmaceuticals is estimated to be 0.089875 with the future projection ranging from a low of 0.06475 to a high of 0.115. Please be aware that this consensus of annual earnings estimates for Telix Pharmaceuticals Limited is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.06 Lowest | Expected EPS | 0.12 Highest |
Telix Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Telix Pharmaceuticals' value are higher than the current market price of the Telix Pharmaceuticals stock. In this case, investors may conclude that Telix Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Telix Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 5 | 9.37% | 0.04 | 0.089875 | 0.02 |
Telix Pharmaceuticals Ownership Allocation
Telix Pharmaceuticals shows a total of 334.72 Million outstanding shares. About 99.86 % of Telix Pharmaceuticals outstanding shares are held by general public with 0.14 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Telix Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 783.21 M. Total Income to common stockholders was 49.92 M with profit before taxes, overhead, and interest of 358.28 M.About Telix Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Telix Pharmaceuticals. We calculate exposure to Telix Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telix Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 586.1 M | 615.4 M | |
| Pretax Profit Margin | 0.06 | 0.07 | |
| Operating Profit Margin | 0.09 | 0.10 | |
| Net Profit Margin | 0.06 | 0.06 | |
| Gross Profit Margin | 0.59 | 0.61 |
Telix Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 345.2 M | |
| Forward Price Earnings | 54.9451 |
Telix Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Telix Pharmaceuticals Limited and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Telix we look at many different elements of the entity such as Telix's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Telix Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Telix Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Telix Pharmaceuticals' worth.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.